Editor-in-chief
Maria Stella Graziani

Deputy Director
Martina Zaninotto

Associate Editors
Ferruccio Ceriotti
Davide Giavarina
Bruna Lo Sasso
Giampaolo Merlini
Martina Montagnana
Andrea Mosca
Paola Pezzati
Rossella Tomaiuolo
Matteo Vidali

International Advisory Board Khosrow Adeli Canada
Sergio Bernardini Italy
Marcello Ciaccio Italy
Eleftherios Diamandis Canada
Philippe Gillery France
Kjell Grankvist Sweden
Hans Jacobs The Netherlands
Eric Kilpatrick UK
Magdalena Krintus Poland
Giuseppe Lippi Italy
☩Howard Morris Australia
Mario Plebani Italy
Sverre Sandberg Norway
Ana-Maria Simundic Croatia
☩Jill Tate Australia
Tommaso Trenti Italy
Cas Weykamp The Netherlands
Maria Willrich USA
Paul Yip Canada


Publisher
Biomedia srl
Via L. Temolo 4, 20126 Milano

Responsible Editor
Giuseppe Agosta

Editorial Secretary
Arianna Lucini Paioni
Biomedia srl
Via L. Temolo 4, 20126 Milano
Tel. 0245498282
email: biochimica.clinica@sibioc.it



Area soci
Non possiedi o non ricordi la password!
Clicca qui

BC: Articoli scritti da S. Dudiez

Il laboratorio nella diagnosi di deficit dell’ormone della crescita e nel monitoraggio dell'aderenza alla terapia sostitutiva
The laboratory role in the diagnosis of growth hormone deficiency and in the monitoring of the adherence toreplacement therapy
<p>Growth hormone deficiency (GHD) is a disorder characterized by the inadequate secretion of GH, which results in short stature reflected by the delay in the bone lengthening, that is inappropriate to the chronological age of the child. Laboratory tests are very important to determine whether the growth-delayed child actually has GHD. These tests are intended to stimulate the pituitary gland to secrete GH, allowing the measuring of its levels in blood at timed intervals. In a 7-year-old child arrived at our attention for deceleration of growth rate, laboratory tests excluded other causes of short stature and the GH measurement confirmed the deficit of this hormone. The patient started the therapy using the recombinant human growth hormone (rhGH). Serum insulin-like growth factor-1 (IGF-1) concentration was monitored during the treatment to help with dose adjustment and to determine the adherence to therapy by the child.</p>
Biochimica Clinica ; 17(1)
Casi Clinici - Case Report